December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

14.35 USD +1.44 (+11.15%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Altimmune Inc

< Previous 1 2 3 4 Next >
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
From GlobeNewswire News Releases
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
From GlobeNewswire News Releases
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
From GlobeNewswire News Releases
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
Preclinical data suggest potential for ALT-801 to address a significant unmet medical need; Phase 1 data readout anticipated in Q2 2021 
From GlobeNewswire News Releases
Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?
InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT. 
From PR Newswire
Thinking about buying stock in Altimmune, General Electric, Moderna, Delta Air Lines, or Norwegian Cruise Line?
InvestorsObserver issues critical PriceWatch Alerts for ALT, GE, MRNA, DAL, and NCLH. 
From PR Newswire
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
From GlobeNewswire News Releases
Altimmune to Present at Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
More Comprehensive Diagnostics are Needed as Cases Surge Once More
FinancialBuzz.com News Commentary 
From PR Newswire
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about buying stock in Xperi, Transocean, Fulgent Genetics, Vaxart, or Altimmune?
InvestorsObserver issues critical PriceWatch Alerts for XPER, RIG, FLGT, VXRT, and ALT. 
From PR Newswire
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
From GlobeNewswire News Releases
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
From GlobeNewswire News Releases
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
From GlobeNewswire News Releases
Altimmune to Present at Two Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
Thinking about buying stock in Altimmune, Dynavax Technologies, GoPro, BioNTech, or Outlook Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for ALT, DVAX, GPRO, BNTX, and OTLK. 
From PR Newswire
Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for DOYU, ADMP, ALT, FCEL, and OVID. 
From PR Newswire
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate
From GlobeNewswire News Releases
Altimmune to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID™ and T-COVID™ – at the World Vaccine Congress
From GlobeNewswire News Releases
Thinking about buying stock in Workhorse Group, Altimmune, Endo International, Inovio Pharmaceuticals, or Kaleido Biosciences?
InvestorsObserver issues critical PriceWatch Alerts for WKHS, ALT, ENDP, INO, and KLDO. 
From PR Newswire
New Challenges Spur Greater Innovation in Diagnostic Testing Capabilities
- FinancialBuzz.com News Commentary 
From PR Newswire
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
Company anticipates first-in-human trials to start in Q4 2020 
From GlobeNewswire News Releases
Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress™ 2020
From GlobeNewswire News Releases
Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID™
Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates 
From GlobeNewswire News Releases
Thinking about trading options or stock in Novavax Inc, Apple Inc, Carnival Corp, United Airlines, or Altimmune Inc?
InvestorsObserver issues critical PriceWatch Alerts for NVAX, AAPL, CCL, UAL, and ALT. 
From PR Newswire
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
From GlobeNewswire News Releases
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.